Canakinumab (an interleukin 1β inhibitor) is a breakthrough in the possibilities of anti-inflammatory therapy for gout
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2013-11-01
|
| Series: | Научно-практическая ревматология |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/1156 |